Once you decide to initiate oral treatment, what regimen, in what sequence and frequency of dosing, are currently recommended? Whatt are the expected microbial conversion rates based on the patient’s underlying disease and other risk factors?
Presenter
Director of University of Miami and VA Sarcoidosis Programs
Co-Director UM NTM Program
IRB Vice-Chairman, Miami VA Healthcare System
Assistant Professor of Department of Medicine
Assistant Professor of Clinical Public Health Sciences
Division of Pulmonary